Hanemann, Oliver - Plymouth University

个人简介

Role Director Institute of Translational and Stratified Medicine Chair of Clinical Neurobiology Plymouth University Peninsula School of Medicine and Dentistry Neurology Consultant Plymouth Hospital NHS Trust Qualifications I trained at Medical School in Hamburg, Glasgow, Johns Hopkins and Harvard. After a DFG research fellowship in molecular neurobiology, in which I cloned the myelin protein PMP22 together with P Spreyer, I was neurology registrar at Medical School in Duesseldorf with Prof Freund. During that period I participated in resolving gene-defect and pathogenesis of the most frequent hereditary neuropathy CMT1A, became lecturer for Neurology and Neurobiology and honorary consultant at that department in 1998 and started work on benign glial tumours. From 2000 I was consultant incl. clinical lead and senior lecturer at the medical school in Ulm with Prof Ludolph continuing my work on benign glia tumours and neuropathies focussing more on motor neuropathies. During that time I was also trained as a medical geneticist. In 2005 I became chair of clinical neurobiology at the Peninsula medical school establishing clinical neurobiology research and administering different independent researcher groups. I successfully bridge basic and clinical sciences. I have been Associate Medical Director for R&D Plymouth Hospital NHS Trust and and Academic lead department of Neurology PHNT My new role at PU PSMD is Director of the Institute for Translational and Stratified Medicine where my remit is to champion research across traditional boundaries and focus on world-leading research. Roles on external bodies Nationally I am neurology lead in the Peninsula Neurooncology network, member NCRI brain tumour group and DeNDRON, (currently research director MND in the SW) member of scientific advisory boards (e.g. CTF, Lord Dowding Fund, Brain Research Trust), member of the council of the British Neuro-Oncology Society (BNOS). I am reviewer for more than 17 international journals including Brain, Cancer Res, Oncogene and Human Mol Gen, and reviewer for a variety of granting agencies incl Wellcome, MRC, CR-UK and DFG.

研究领域

My own focus is on neuromuscular disease esp. motor neuron disease and neurooncology. I supervised more than 15 PhD students quite a few finished with distinction and started a career in academia. Our current work on motor neuron disease is mainly clinical and includes genotype-phenotype analysis and clinical trials. In neurooncology we focus on cell biology studies to find and validate new therapeutic targets as there is a great medical need to find new treatments (summarized in Hanemann 2008, Ammoun and Hanemann 2011). Following our aim to work translational I also look after many patients with these diseases as a honorary consultant.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Spreyer, G. Kuhn, C.O. Hanemann, C. P. Gillen, R. Kuhn, G. Lemke, H.W. Müller, (1991) Axon regulated expression of a Schwann cell mRNA homologous to a growth arrest specific gene, EMBO Journal 10 (12) 3661-3668 Matsunami N., Smith B., Ballard L., Lensch M.W., Robertson M., Albertson H., Hanemann C.O., Müller H.W., et al. (1992), Peripheral myelin protein-22 gene maps in the duplication in chromosome 17 p11.2 associated with Charcot-Marie-Tooth 1A, Nature Genetics 1 176-179 CO Hanemann, Stoll G, Müller HW (1995) PMP22 expression in CMT1A neuropathy. Ann Neurol 37(1): 136 CO Hanemann, Gabreëls-Festen AAWM, Müller HW, Stoll G (1996) Low affinity NGFR expression in CMT1A nerve biopsies. Brain 119: 1461-1469 CO Hanemann, Müller HW (1998). Pathogenesis of CMT1A neuropathy, Trends in Neuroscience 21: 282-286 CO Hanemann, D D´Urso, AAWM Gabreels:Festen, HW Müller (2000). Altered distribution of PMP22 in nerve biopsies from CMT1A patients with different PMP22 mutations, Brain 123:1001-6 Sperfeld AD, Hein C, Schröder JM, Ludolph AC Hanemann CO (2002) Occurrence and characterisation of peripheral nerve involvement in Neurofibromatosis Type 2 Brain 125:996-1004 Schulze K, Hanemann CO*, Müller HE, Hanenberg H (2002) Transduction of wt-merlin into human schwannomma cells decreases schwannoma cell growth and induces apoptosis. Human Molecular Genetics 11 (1) 69-76 *Corresponding author Kämpchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO (2003) Upregulation of the Rac1/JNK signalling pathway in primary human schwannoma cells, Human Molecular Genetics 12: 1211-21,